Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.